AL-1 is a potent O2- generation inhibitor (IC50 = 7.6 μM) through the inhibition of leukocytic NADPH oxidase. AL-1 inhibits 12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced H2O2 production. AL-1 reduces tumor incidence in ICR mouse skin. AL-1 can be used for research on oxidative stress-related diseases including cancer.

Sigma-2 Receptor ligand 1 (Compound 7i) is a highly selective Sigma-2 receptor ligand with a Ki value of 40 nM. Sigma-2 Receptor ligand 1 is promising for research of Alzheimer's disease.

S-14489 is an orally active selective postsynaptic 5-HT1A receptor antagonist with a pKi of 9.2. S-14489 can act as a 5-HT1A autoreceptor agonist and inhibit striatal 5-hydroxytryptophan accumulation. S-14489 can be used for the research of neurological disease.

ZJH-16 (Compound 11e) is an orally active EED inhibitor (IC50 = 2.72 nM, Kd = 4.4 nM). ZJH-16 inhibits the growth of lymphoma cells and reduces H3K27 trimethylation levels. ZJH-16 inhibits tumor growth in lymphoma animal models. ZJH-16 can be used for research on lymphoma and other cancers.

SDZ-62-434 (free base) is a platelet-activating factor (PAF) antagonist. SDZ-62-434 (free base) has antiproliferative activity in human solid and haematological malignancies.

4-(Cyclohexyldisulfaneyl)pyridine is a Type III secretion system (T3SS) inhibitor that suppresses the promoter activity of T3SS-related genes (hrpA and hrpL) in Erwinia amylovora CFBP1430. 4-(Cyclohexyldisulfaneyl) pyridine can be utilized in study on fire blight disease.

IO-21 (Compound 3) is a candidate cytoprotective agent. IO-21 exhibits a marked cytoprotective effect. IO-21 shows a potent inhibitory activity against HCl•ethanol-induced lesions. IO-21 shows a MIC of 50 μg/mL against Helicobacter pylori 7795. IO-21 can be used in the research of gastric mucosal ulcers.

Phenethyl 4-ANPP is a MOR (μ-opioid receptor) agonist. Phenethyl 4-ANPP is an analytical reference standard that is structurally similar to known opioids.

T2M-010 is a potent, brain-penetrant TREM2 agonist (Kd = 0.83 μM). T2M-010 activates receptor-proximal signaling, inducing SYK phosphorylation in TREM2-expressing cells, and promotes microglial phagocytosis. T2M-010 can be used for the study of protective microglial responses relevant to Alzheimer’s disease (AD).

UNC9750 is an inositol phosphate multikinase (IPMK) inhibitor with IC50 values ​​of 31.6 and 374 nM for IPMK and IP6K2, respectively.. UNC9750 inhibits cellular accumulation of InsP5, the direct product of IPMK kinase activity, while having no effect on either InsP6 or InsP7 levels. UNC9750 has ≥ 75% inhibition of four kinases (DAPK1, DYRK1B, PDGFR, and KDR). UNC9750 can be used for the study of glioblastoma.

SCR007 is a synthetic carbohydrate receptor (SCR) with broad-spectrum antiviral activity. SCR007 inhibits the entry of enveloped viruses across multiple families (Coronaviridae: SARS-CoV-1, SARS-CoV-2, MERS-CoV; Filoviridae: EBOV, MARV; Paramyxoviridae: NiV, HeV) and the glycosylated nonenveloped rotavirus. SCR007 binds viral envelope N-glycans, blocking viral binding to host cells or both binding and membrane fusion. SCR007 exerts prophylactic effects in hACE2 mice infected with SARS-CoV-2. SCR007 can be used for the study and prevention of enveloped virus pandemics.

SCR005 is a synthetic carbohydrate receptor (SCR) with broad-spectrum antiviral activity. SCR005 inhibits the entry of enveloped viruses across multiple families (Coronaviridae: SARS-CoV-1, SARS-CoV-2, MERS-CoV; Filoviridae: EBOV, MARV; Paramyxoviridae: NiV, HeV) and the glycosylated nonenveloped rotavirus. SCR005 binds viral envelope N-glycans, blocking viral binding to host cells or both binding and membrane fusion. SCR005 exerts prophylactic effects in hACE2 mice infected with SARS-CoV-2. SCR005 can be used for the study and prevention of enveloped virus pandemics.

Bis(vinylsulfonyl)piperazine-triazole-PEG3-O-diisopropylsilyl-Cl is a cleavable and silyl ether-based ADC linker that can be used in the synthesis of antibody-drug conjugates (ADC).

AG-1859 is a viral protease inhibitor. AG-1859 can be used in the research of viral infection.

ML085 is an inhibitor of placental alkaline phosphatase (PLAP). ML085 can be used in the research of testicular tumors, endocrine and metabolic diseases, and genitourinary system diseases.

C3361 is a moderate specific Plasmodium falciparum hexose transporter 1 (PfHT1) and Plasmodium berghei hexose transporter 1 (PbHT1) inhibitor with Ki values of 8.6 and 9.4 μM. C3361 inhibits TgGT1 with a Ki of 82 μM. C3361 attenuates hepatic (IC50 = 15 μM) and ookinete development of P. berghei. C3361 can suppress the growth of blood-stage parasites. C3361 can be used for the research of infection, such as malaria.

TH16 is an antibacterial agent (MIC=2 μg/mL against methicillin-resistant Staphylococcus aureus, MRSA). TH16 disrupts bacterial cytoplasmic membrane integrity, elevating intracellular reactive oxygen species (ROS) levels to induce bacterial death. TH16 is promising for research of bacterial infection.

PROTAC Her3-binding moiety 2 is a Her3 inhibitor. PROTAC Her3-binding moiety 2 can be used for synthesis of PROTAC Her3 Degrader-8.

Enozertinib (ORIC-114) hemihydrate is the inhibitor for EGFR that exhibits antineoplastic activity.

EGFR Ligand-Linker Conjugates 1 is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for EGFR and a PROTAC linker, which recruits E3 ligases. EGFR Ligand-Linker Conjugates 1 can be used for synthesis of PROTAC EGFR degrader 3.

EN1033 is a covalent Immune regulatory transcription factor 5/8 (IRF5/8) degrader. EN1033 destabilizes and degrades IRF5 and IRF8 by covalently targeting cysteine residues C28 and C223, respectively, inhibiting their pro-inflammatory transcriptional activity, such as the reduced mRNA level of IL1A, IL1B and CCL2. EN1033 can be used for autoimmune and inflammatory diseases research.

PF-06658607 is an alkynylated irreversible Brutons tyrosine kinase (BTK) inhibitor that covalently reacts with active site cysteines in the ATP-binding pocket. PF-06658607 can be used to detect "off "-targets for covalent kinase inhibitors in cancer cells. The alkyne moiety allows for azide-based detection probe via copper-catalyzed click chemistry.

LXH-3-71 is a potent molecular glue PHGDH degrader. LXH-3-71 forms a dynamic chimera between PHGDH and the DDB1-CRL E3 ligase. LXH-3-71 modulates the stemness of colorectal cancer cells (CRCs) both in vitro and in vivo. LXH-3-71 can be used for colorectal cancer research.

ALOX5 stabilizer-1 is an arachidonate 5-lipoxygenase (ALOX5) stabilizer with a Kd of 7.26 μM. ALOX5 stabilizer-1 inhibits β-catenin protein levels and then suppresses STAT3 signal pathway. ALOX5 stabilizer-1 induces lung cancer cells apoptosis, inhibited cell migration and proliferation. ALOX5 stabilizer-1 can used for the study of non-small cell lung cancer (NSCLC).

CDRI-97/78 is an antimalarial agent. CDRI-97/78 has phototoxicity and can induce cell apoptosis and G2/M phase arrest. CDRI-97/78 can be used for the research of infection.

ISM7594 is an orally active FGFR2/3 inhibitor. ISM7594 shows broad-spectrum antiproliferative potency in FGFR2- or FGFR3-altered cancer cell panels, including FGFR2/3 amplification, fusion, and mutation (BaF3-TEL-FGFR2-V564F (IC50 = 0.067 nM), BaF3-TEL-FGFR2-V564I (IC50 = 2 nM)) types. ISM7594 inhibits tumor growth in a dose-dependent manner. ISM7594 can be used for the study of advanced solid tumors with FGFR2/3 aberrations.

RJW103 is a selective steroidogenic factor-1 (SF-1, NR5A1) agonist with a pEC50 of 6.5. RJW103 shows a pEC50 of 5.9 for liver receptor homologue-1 (LRH-1, NR5A2). RJW103 can be used for the researches of cancer, endocrinology and metabolic disease, such as adrenal cortex neoplasms.

[Ru(dpp)(bpy)(mtmp)](PF6)2 (Compound 5) is a trisheteroleptic ruthenium complex. [Ru(dpp)(bpy)(mtmp)](PF6)2 has a light-activated anticancer activity. [Ru(dpp)(bpy)(mtmp)](PF6)2 can selectively cleave off upon green light irradiation, thereby releasing a phototoxic ruthenium-based photoproduct that binds to nuclear DNA, induces DNA damage and apoptosis in cancer cells. [Ru(dpp)(bpy)(mtmp)](PF6)2 can be used for phototherapy of cancers like conjunctival melanoma research.

JNJ-17166864 is a highly selective CCR2 antagonist. JNJ-17166864 has low oral bioavailability. JNJ-17166864 can significantly reduce the area of alveolar bone loss in a mouse model of periodontitis induced by Porphyromonas gingivalis infection. JNJ-17166864 can be used in the research of inflammatory diseases such as allergic rhinitis and periodontitis.

SM (d18:1/15:0) is a sphingomyelinase inhibitor. SM (d18:1/15:0) is promising for research of neurodegenerative diseases (e.g., Alzheimer's) and metabolic syndrome.